---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-013615"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:11:02.322450+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BiomX raises ~$7.5M in PIPE; reports positive Phase 1b/2a data for BX004 in CF

## Summary
- Private placement of 30.6M shares at $0.245; gross proceeds ~$7.5M in two closings.
- First closing of ~$1.5M (5.98M securities) imminent; second closing contingent on shareholder approval.
- Part 1 Phase 1b/2a: BX004 reduced P. aeruginosa by -1.42 log10 CFU/g vs -0.28 placebo at Day 15.
- No safety events or emerging resistance; phages detected in all treated patients during dosing.
- Part 2 (24 patients) expected Q3 2023; proceeds to fund BX004 CF development and working capital.

## SEC filing metadata
- accession: 0001213900-23-013615
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/0001213900-23-013615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/ea174091-8k_biomxinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-013615
- JSON: https://secwatch.observer/filing/0001213900-23-013615.json
- Plain text: https://secwatch.observer/filing/0001213900-23-013615.txt

## Key facts
- Material Agreements
  BiomX Inc. entered into Securities Purchase Agreement with accredited and non-U.S. investors valued at approximately $7.5 million gross proceeds (effective 2023-02-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited and non-U.S. investors
  - Value: approximately $7.5 million gross proceeds
  - Effective: 2023-02-22
  source text: On February 22, 2023, BiomX Inc. (the “ Company ”) executed a definitive Securities Purchase Agreement (the “ SPA ”) with accredited and non-U.S. investors relating to a private placement (the “ Offering ”) of an aggregate of 30,608,163 shares of the Company’s common stock (“ Shares ”), including shares issuable upon the exercise of pre-funded warrants (“ Pre-Funded Warrants ”) to purchase additional shares of the Company’s common stock (each, a “ Security ” and collectively, the “ Securities ”), at a purchase price of $0.245 per Share and $0.244 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/0001213900-23-013615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.